A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
There is no standard treatment for chondrosarcoma. Some small sample of studies has shown
that anti-angiogenic TKIs show certain activity in the treatment of chondrosarcoma. PD-1
inhibitors, in recent years, have also been used in clinical practice and showed good
efficacy. We intend to explore the response of chondrosarcoma to PD-1 monoclonal antibody and
the influence of different IDH genotypes on PD-1 monoclonal antibody response.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University